Larvol Delta - Viracta-Therapeutics-Announces-Notice-of-Allowance-for-US-Patent-Application-Covering-the-Use-of-its-Combination-Product-Candidate-for-the-Treatment-of-EpsteinBarr-Virusassociated-Lymphoma

nanatinostat (VRx-3996) - Viracta Therap

https://www.prnewswire.com/news-releases/viracta-therapeutics-announces-notice-of-allowance-for-us-patent-application-covering-the-use-of-its-combination-product-candidate-for-the-treatment-of-epstein-barr-virus-associated-lymphoma-301228559.html

Feb 16, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next